Currently out of the existing stock ratings of Jason Zemansky, 13 are a BUY (54.17%), 10 are a HOLD (41.67%), 1 are a SELL (4.17%).

Jason Zemansky

Work Performance Price Targets & Ratings Chart

Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 46.53% that have a potential upside of 19.48% achieved within 86 days.

Jason Zemansky’s has documented 47 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on INSM, Insmed at 09-Oct-2024.

Wall Street Analyst Jason Zemansky

Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for INSM (INSMED) at 5/24/2024. The price target of $40 was fulfilled within 4 days with a profit of $18 (81.82%) receiving and performance score of 204.55.

Average potential price target upside

ALLK Allakos CYTK Cytokinetics ESPR Esperion Therapeutics INSM Insmed HOWL Werewolf Therapeutics RCUS Arcus Biosciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$1.73 (136.22%)

$3

1 months 10 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Hold

$7

4 months 16 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

57

Sell

$1

$-0.27 (-21.26%)

$1.5

9 months 19 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Buy

10 months 18 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Buy

$9

$7.73 (608.66%)

1 years 5 months 25 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Zemansky is most bullish on?

Potential upside of $17.68 has been obtained for INSM (INSMED)

Which stock is Jason Zemansky is most reserved on?

Potential downside of $0.47 has been obtained for ESPR (ESPERION THERAPEUTICS)

What Year was the first public recommendation made by Jason Zemansky?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?